Xeroderma pigmentosum group D polymorphisms and esophageal cancer susceptibility: A meta-analysis based on case-control studies

Rong Yang, Chong Zhang, Armah Malik, Zhi-Da Shen, Jian Hu, Yi-He Wu

Rong Yang, Department of Radiology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang Province, China
Chong Zhang, Armah Malik, Jian Hu, Yi-He Wu, Department of Thoracic Surgery, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang Province, China
Zhi-Da Shen, College of Medicine, Zhejiang University, Hangzhou 310058, Zhejiang Province, China
Author contributions: Wu YH and Hu J designed the research; Yang R and Zhang C performed the research; Yang R, Malik A and Shen ZD wrote the paper.
Correspondence to: Yi-He Wu, MD, Department of Thoracic Surgery, The First Affiliated Hospital, College of Medicine, Zhejiang University, No. 79 Qingchun Road, Hangzhou 310003, Zhejiang Province, China. drwuyihe@163.com
Telephone: +86-571-87236847 Fax: +86-571-87236847
Received: March 21, 2014 Revised: May 5, 2014
Accepted: July 29, 2014 Published online: November 28, 2014

Abstract

AIM: To clarify the effects of the xeroderma pigmentosum group D (XPD) Asp312Asn and Lys751Gln gene polymorphisms on the risk of esophageal cancer (EC).

METHODS: A computerised literature search was conducted to identify the relevant studies from the PUBMED and EMBASE databases, reviews, and reference lists of relevant articles. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the associations between the XPD Asp312Asn and/or Lys751Gln polymorphisms and EC susceptibility. Statistical analyses were performed using the software Stata 12.0. A fixed or random effects model was selected based on the heterogeneity test. Publication bias was estimated using funnel plots and Egger’s linear regression method. Subgroup analyses were performed based on histological type and ethnicity.

RESULTS: Thirteen case-control studies with a total of 10 comparisons for the Asp312Asn polymorphism, including 2373 cases and 3175 controls, and 15 comparisons for the Lys751Gln polymorphism, including 3226 cases and 5237 controls, were recruited for the meta-analysis. In terms of the XPD Asp312Asn polymorphism, significantly increased EC risks were identified in the Asp/Asn vs Asp/Asp comparison (OR = 1.17, 95%CI: 1.02-1.33, P = 0.03) and in the dominant-model comparison (Asn/Asn+Asp/Asn vs Asp/Asp: OR = 1.18, 95%CI: 1.04-1.34, P = 0.01). However, no significant associations were found in the Asn/Asn vs Asp/Asp comparison (OR = 1.30, 95%CI: 1.00-1.70, P = 0.05) or in the recessive-model comparison (Asn/Asn vs Asp/Asp: OR = 1.17, 95%CI: 0.91-1.50, P = 0.22). In terms of the XPD Lys751Gln polymorphism, a significant association with EC susceptibility was found under the recessive model (Gln/Gln vs Lys/Lys: OR = 1.21, 95%CI: 1.00-1.43, P = 0.03). However, no associations were identified in the other comparisons (co-dominant model: Lys/Gln vs Lys/Lys: OR = 1.14, 95%CI: 0.94-1.31, P = 0.20; Gln/Gln vs Lys/Lys: OR = 1.31, 95%CI: 0.98-1.75, P = 0.07; dominant model: OR = 1.14, 95%CI: 0.96-1.35, P = 0.14).

CONCLUSION: The results of this meta-analysis suggest that the XPD Asp312Asn and Lys751Gln gene polymorphisms are associated with a significantly increased risk for EC.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

Key words: Esophageal cancer; Xeroderma pigmentosum group D; Polymorphism; Meta-analysis

Core tip: To clarify the effects of xeroderma pigmentosum group D (XPD) gene polymorphisms on the risk of esophageal cancer (EC), we performed a meta-analysis of all of the case-control studies that evaluated the association between the genetic polymorphisms of
XPD (Asp312Asn and Lys751Gln) and EC susceptibility. Thirteen case-control studies were recruited in the meta-analysis. For the XPD Asp312Asn polymorphism, significantly increased EC risks were found in the Asp/Asn vs Asp/Asp comparison and in the dominant model comparison. For the XPD Lys751Gln polymorphism, a significant association between the XPD Lys751Gln polymorphism and EC susceptibility was found under the recessive model.

Yang R, Zhang C, Malik A, Shen ZD, Hu J, Wu YH. Xeroderma pigmentosum group D polymorphisms and esophageal cancer susceptibility: A meta-analysis based on case-control studies. World J Gastroenterol 2014; 20(44): 16765-16773 Available from: URL: http://www.wjgnet.com/1007-9327/full/v20/i44/16765.htm DOI: http://dx.doi.org/10.3748/wjg.v20.i44.16765

INTRODUCTION

Esophageal cancer (EC) is the sixth most frequently diagnosed cancer and the fifth most common cause of cancer death among males[1,2]. The major risk factors for EC are not well understood but are thought to include smoking, excessive alcohol consumption, poor nutritional status, low intake of fruits and vegetables, etc.[2-5]. Several studies have suggested that the genes involved in the DNA repair system play a crucial role in protecting against mutations, while a decreased DNA repair capacity is viewed as a crucial event in carcinogenesis[6]. The xeroderma pigmentosum group D (XPD) enzyme, an evolutionarily conserved ATP-dependent helicase, plays an important role in the repair of bulky DNA adducts, such as pyrimidine dimers, photoproducts and cross-links[7,8]. Mutations at different sites in the XPD gene can give rise to repair and transcription defects, and altered DNA repair capacity can render a higher risk of developing different types of cancer[9-11]. Several single nucleotide polymorphisms (SNPs) have been identified in the XPD gene. Among them, Asp312Asn (rs1799793 G>A) and Lys751Gln (rs13181 T>G) are commonly identified and result in amino acid changes.

Currently, there are many molecular epidemiological studies exploring the associations between the genetic polymorphisms of XPD, particularly Asp312Asn and Lys751Gln, and EC susceptibility, but the results remain controversial rather than conclusive. To address the inconsistencies in the findings of these studies, we performed a meta-analysis, based on published case-control studies, to derive a more precise estimation of the association between these two XPD polymorphisms and EC susceptibility.

MATERIALS AND METHODS

Search strategy

We systematically searched PubMed, Embase, previous reviews and the reference lists from identified articles published up to January 1, 2014 for studies related to EC and genetic polymorphisms[9,11]. We used the following search terms: “ERCC2” or “XPD” or “xeroderma pigmentosum group D” or “excision repair cross-complementing group 2” or “DNA repair gene”, “polymorphism” or “variant”, “esophageal” or “esophagus”, and “cancer” or “carcinoma” or “squamous cell” or “adenocarcinoma”, of which the exploration was limited to human studies. No language restrictions were imposed, and all of the eligible studies were examined carefully, and their references were checked for other relevant publications. All of the literature findings were independently reviewed by two professional co-workers (Yang R. and Wu Y) to identify the studies that met the following criteria: (1) case-control study design; (2) evaluating the associations between XPD polymorphisms (Asp312Asn and/or Lys751Gln) and EC susceptibility; and (3) reporting the odds ratio (OR) and the corresponding 95% confidence intervals (CIs), or the size of the sample. Any differences were resolved by consensus. The major excluding criteria included the following: (1) not a case-control study; (2) review publications; or (3) overlapping data.

Data extraction

We used a standardised data extraction method to extract the data from the included papers[11]. Information was collected from each article, including the first author, year of publication, country, journal, racial descent of the study population, demographics, number of cases and controls for each genotype, genotyping method, histological type and confirmation of diagnosis. While the allele frequencies were not given, they were calculated from the corresponding genotype frequencies of the case and control groups.

Statistical analysis

The ORs were employed to evaluate the associations between the XPD Asp312Asn and/or Lys751Gln polymorphisms and EC susceptibility[9,11]. For Asp312Asn, the pooled ORs were calculated for a co-dominant model (Asp/Asn vs Asp/Asp), a recessive model (Asn/Asn+Asp/Asn vs Asp/Asp), a dominant model (Asn/Asn+Asp/Asn vs Asp/Asp), a recessive model (Asn/Asn vs Asp/Asp+Asn/Asp) and an additive model [(2Asn/Asn+Asp/Asn vs 2(Asp/Asn+Asn/Asp+Asp)]. We evaluated the risks of the same four models for the Lys751Gln genotype as well.

The χ² goodness-of-fit test was used to evaluate whether the genotypes among the control subjects conformed to the Hardy-Weinberg equilibrium (HWE). We applied two models of meta-analysis for any dichotomous outcomes according to the results of heterogeneity tests among the individual studies, using the software Stata 12.0 (Stata Corp., College Station, TX, United States): the fixed-effects model (the Mantel-Haenszel method) and the random-effects model (the DerSimonian and Laird method)[11]. Subgroup analyses were performed based on histological type and ethnicity. The publication bias was investigated with a funnel plot, in which the standard error (SE) of log (OR) for each study was plotted against
Asp312Asn:

the respective log (OR). The funnel plot asymmetry was assessed using Egger’s linear regression method. The significance of the intercept was determined by the t-test, and P < 0.05 was considered statistically significant. All of the statistical tests were performed using Stata version 12.0. All of the P-values were two-sided.

RESULTS

Eligible studies

A total of 136 articles were identified by the combined database search (PubMed and Embase) and manual approach (searching the previous studies cited in previous reviews and use of the reference lists from identified articles) of case-control studies, of which 13 case-control studies satisfied the inclusion criteria. After reading the full texts, two studies by Liu et al17 and Huang et al18 were excluded because the subjects had also been included in the studies by Tse et al19 or Huang et al20. Therefore, 13 case-control studies were eventually included in the meta-analysis. Figure 1 presents a flowchart of the retrieved and excluded studies with a specification of reasons. Table 1 shows the characteristics of the included studies. Overall, of the 13 included studies, a total of 10 comparisons, including 2373 cases and 3175 controls, for the Asp312Asn polymorphism, and 15 comparisons, including 3226 cases and 5237 controls, for the Lys751Gln polymorphism were reviewed. The distribution of genotypes in the controls of all of the included studies was in accordance with the HWE.

Meta-analysis

XP D Asp312Asn: Table 2 indicates the associations between the XP D Asp312Asn polymorphism and EC susceptibility. Significantly increased risks were found in the Asp/Asn vs Asp/Asp comparison (OR = 1.17, 95%CI: 1.02-1.33, P = 0.03, Table 2) and in the dominant model comparison (Asp/Asn + Asp/Asp vs Asp/Asp: OR = 1.18, 95%CI: 1.04-1.34, P = 0.01, Figure 2, Table 2). However, no significant associations were found in the Asn/Asn vs Asp/Asp comparison (OR = 1.30, 95%CI: 1.00-1.70, P = 0.05, Table 2) or in the recessive model comparison (Asn/Asn vs Asp + Asp/Asp: OR = 1.17, 95%CI: 0.91-1.50, P = 0.22, Table 2). In the subgroup analysis according to cancer type [esophageal squamous cell carcinoma (ESCC) or esophageal adenocarcinoma (EADC)], significant associations between the XP D Asp312Asn polymorphism and EC susceptibility were detected in the EADC subgroup in the co-dominant model (Asp/Asn vs Asp/Asp: OR = 1.26, 95%CI: 1.03-1.53, P = 0.02, Asn/Asn vs Asp/Asp: OR = 1.40, 95%CI: 1.04-1.89, P = 0.03, Table 2) and the dominant model (OR = 1.29, 95%CI: 1.07-1.55, P = 0.01, Figure 2, Table 2). Further analysis by ethnicity revealed significant associations of the XP D Asp312Asn polymorphism with EC susceptibility in non-Chinese populations in the Asp/Asn vs Asp/Asp comparison (OR = 1.23, 95%CI: 1.03-1.47, P = 0.02, Table 2) and in the dominant model comparison (OR = 1.24, 95%CI: 1.05-1.47, P = 0.01, Table 2, Figure 3), but the same associations were not seen in Chinese populations. Finally, for the additive model (Table 2), individuals carrying the 312Asn allele were not significantly associated with an increased risk for EC (OR = 1.10, 95%CI: 1.00-1.21, P = 0.06).

XP D Lys751Gln: Table 3 lists the overall results of the meta-analysis for the associations between the XP D Lys751Gln polymorphism and EC susceptibility. There was a significant association with EC susceptibility for the recessive model comparison (Gln/Gln vs Lys/Gln + Lys/Lys: OR = 1.21, 95%CI: 1.02-1.43, P = 0.03, Figure 4, Table 3). However, such associations were not found in the other comparisons (co-dominant model: Lys/Gln vs Lys/Lys: OR = 1.11, 95%CI: 0.94-1.31, P = 0.20; Gln/Gln vs Lys/Lys: OR = 1.31, 95%CI: 0.98-1.75, P = 0.07; dominant model: OR = 1.14, 95%CI: 0.96-1.35, P = 0.14, Table 3). In the stratified analysis based on cancer type (ESCC or EADC), we observed an OR of 1.44 (95%CI: 1.01-2.06, P = 0.05, Table 3) for ESCC risk and an OR of 1.26 (95%CI: 1.02-1.56, P = 0.03, Table 3) for EADC risk, when comparing the Gln/Gln type to the wild type Lys/Lys (Table 3). When stratified by ethnicity, statistically significantly elevated risks were found in Chinese populations in the Gln/Gln vs Lys/Lys comparison (OR = 2.49, 95%CI: 1.44-4.29, P = 0.001, Table 3) and in the recessive model comparison (OR = 2.37, 95%CI: 1.38-4.10, P = 0.002, Figure 5, Table 3), but the same associations were not identified in non-Chinese populations. Finally, for the additive model (Table 3), individuals carrying the 751Gln allele were not significantly associated with an increased risk for EC (OR = 1.10, 95%CI: 0.99-1.22, P = 0.10, Table 3).

Heterogeneity and sensitivity analysis

There was moderate heterogeneity among the studies that described the XP D Asp312Asn polymorphism (co-dominant model: Asp/Asn vs Asp/Asp, P = 0.97; Asn/Asn vs
Table 1 Characteristics of the studies included in the meta-analysis

| Ref. | Country | Ethnicity | Control source | Cancer type | Genotype distribution (case/control) | P for HWE |
|------|---------|-----------|----------------|-------------|-------------------------------------|----------|
|      |         |           |                | Asp312Asn   | Lys751Gln                           |          |
|      |         |           |                | Asp/Asp     | Asp/Asn    | Asn/Asn | Lys/Lys | Lys/Gln | Gln/Gln | Asp312Asn | Lys751Gln |
| Xing et al. 2002 | China | Chinese | PB | ESCC | 381/461 | 49/62 | 3/1 | 367/451 | 63/70 | 3/3 | 0.47 | 0.87 |
| Xing et al. 2003 | China | Chinese | PB | ESCC | 286/338 | 38/45 | 1/0 | 278/331 | 44/49 | 3/3 | 0.22 | 0.43 |
| Yu et al. 2004 | China | Chinese | HB | ESCC | 121/136 | 14/16 | 0/0 | 108/133 | 16/17 | 11/2 | 0.49 | 0.11 |
| Casson et al. 2005 | Canada | Caucasian | HB | EADC | - | - | - | 31/34 | 21/46 | 4/15 | - | 0.93 |
| Ye et al. 2006 | Sweden | Swedish | PB | EADC | 31/176 | 51/237 | 14/57 | 27/198 | 51/203 | 18/71 | 0.09 | 0.11 |
| Sebti et al. 2007 | India | Indian | HB | ESCC | - | - | - | 52/63 | 61/77 | 7/20 | - | 0.64 |
| Dooeke et al. 2008 | Australia | Mixed | PB | EADC | - | - | - | 108/575 | 123/588 | 32/174 | - | 0.22 |
| Ferguson et al. 2008 | Ireland | Caucasian | PB | EADC | - | - | - | 80/91 | 94/121 | 34/35 | - | 0.61 |
| Tse et al. 2008 | United States | Mixed | HB | EADC | 117/199 | 150/206 | 43/49 | 104/193 | 159/208 | 49/52 | 0.69 | 0.72 |
| Pan et al. 2009 | United States | Caucasian | HB | ESCC | 16/201 | 20/185 | 1/48 | 17/187 | 21/216 | 3/53 | 0.58 | 0.43 |
| Zhai et al. 2009 | China | Chinese | HB | ESCC | - | - | - | 167/148 | 31/51 | 2/1 | - | 0.12 |
| Huang et al. 2012 | China | Chinese | HB | ESCC | 171/298 | 42/60 | 0/0 | 150/274 | 55/79 | 8/5 | 0.08 | 0.80 |
| Li et al. 2013 | China | Chinese | PB | ESCC | 342/351 | 56/47 | 2/2 | 283/321 | 105/73 | 12/6 | 0.75 | 0.43 |

PB: Population-based study; HB: Hospital-based study; ESCC: Esophageal squamous cell carcinoma; EADC: Esophageal adenocarcinoma; HWE: Hardy-Weinberg equilibrium.

Table 2 Results of the meta-analysis for the xeroderma pigmentosum group D Asp312Asn polymorphism and esophageal cancer susceptibility

| Study group | Co-dominant model | Dominant model | Recessive model | Additive model |
|-------------|-------------------|----------------|-----------------|---------------|
|             | Asp/Asn vs Asp/Asn | Asn/Asn vs Asp/Asn | Asn/Asn vs Asp/Asn | Asn/Asn vs Asp/Asn |
|             | OR (95%CI) P Ph    | OR (95%CI) P Ph | OR (95%CI) P Ph | OR (95%CI) P Ph |
| Total       |                   |                   |                   |               |
| Cancer type |                   |                   |                   |               |
| ESCC        | 1.17 (1.02, 1.33) | 0.03 0.97 1.30 (1.00, 1.70) | 0.05 0.75 1.18 (1.04, 1.34) | 0.01 0.98 1.17 (0.91, 1.50) |
| EADC        | 1.90 (0.91, 1.30) | 0.35 0.95 0.99 (0.54, 1.79) | 0.48 0.64 1.09 (0.91, 1.30) | 0.35 0.99 0.93 (0.53, 1.63) |
| Ethnicity   | 1.26 (1.03, 1.53) | 0.02 0.97 1.40 (1.04, 1.89) | 0.03 0.89 1.29 (1.07, 1.55) | 0.01 0.99 1.24 (0.94, 1.64) |
| Chinese     | 1.08 (0.88, 1.33) | 0.45 0.88 2.08 (0.57, 7.60) | 0.27 0.66 1.10 (0.90, 1.35) | 0.36 0.93 2.06 (0.57, 7.51) |
| Non-Chinese | 1.23 (1.03, 1.47) | 0.02 0.95 1.27 (0.97, 1.67) | 0.08 0.54 1.24 (1.05, 1.47) | 0.01 0.93 1.14 (0.89, 1.47) |

ESCC: Esophageal squamous cell carcinoma; EADC: Esophageal adenocarcinoma; Ph: P value of the Q-test for heterogeneity.

Asp/Asp, P = 0.75; dominant model: P = 0.98; recessive model: P = 0.71; additive model: P = 1.00), but this was not observed in the Lys751Gln polymorphism (co-dominant model: Lys/Gln vs Lys/Lys, P = 0.01; Gln/Gln vs Lys/Lys, P = 0.03; dominant model: P = 0.001; recessive model: P = 0.11; additive model: P = 0.02). The details are shown in Tables 2 and 3.

A sensitivity analysis was carried out by individually omitting each study included in the meta-analysis, and the subsequent results of each genetic model were not materially altered (data not shown), indicating that the results were statistically robust.

Publication bias

Begg’s funnel plot and Egger’s test were performed to assess any possible publication bias. The shape of the funnel plots did not reveal any obvious asymmetry. We have presented the funnel plots of XPD Asp312Asn for the dominant model (Asn/Asn + Asp/Asn vs Asp/Asp) and XPD Lys751Gln for the recessive model (Gln/Gln vs Lys/Lys) in Figure 6. The statistical evidence from the results of Egger’s test confirmed the funnel...
DISCUSSION

DNA repair enzyme gene polymorphisms that are capable of altering the function or efficiency of damaged DNA repair can lead to genetic instability and carcinogenesis\(^{32}\). A small proportion of published studies have explored the relationship between XPD polymorphisms and EC risk and have yielded inconsistent results\(^{17-31}\). In order to derive a more precise estimation of the relationship, we performed a meta-analysis of 13 case-control studies, including 10 comparisons for the Asp312Asn polymorphism (2373 cases and 3175 controls) and 15 comparisons for the Lys751Gln polymorphism (3226 cases and 5237 controls).

In the case of the XPD Asp312Asn polymorphism, our results indicated that individuals carrying the variant heterozygous Asp/Asn showed an increased risk for EC compared to those with the wild-type homozygous Asp/Asp (OR = 1.17, 95%CI: 1.02-1.33). Similarly, a significant association between the XPD Asp312Asn polymorphism and EC was found under the dominant model (OR = 1.18, 95%CI: 1.04-1.34).

plot symmetry (XPD Asp312Asn: \(P = 0.31\) for Asp/Asn vs Asp/Asp, \(P = 0.77\) for Asn/Asn vs Asp/Asp, \(P = 0.06\) for the dominant model, \(P = 0.89\) for the recessive model, and \(P = 0.11\) for the additive model; XPD Lys751Gln: \(P = 0.38\) for Lys/Gln vs Lys/Lys, \(P = 0.99\) for Gln/Gln vs Lys/Lys, \(P = 0.40\) for the dominant model, \(P = 0.86\) for the recessive model, and \(P = 0.69\) for the additive model).

### DISCUSSION

DNA repair enzyme gene polymorphisms that are capable of altering the function or efficiency of damaged DNA repair can lead to genetic instability and carcinogenesis\(^{32}\). A small proportion of published studies have explored the relationship between XPD polymorphisms and EC risk and have yielded inconsistent results\(^{17-31}\). In order to derive a more precise estimation of the relationship, we performed a meta-analysis of 13 case-control studies, including 10 comparisons for the Asp312Asn polymorphism (2373 cases and 3175 controls) and 15 comparisons for the Lys751Gln polymorphism (3226 cases and 5237 controls).

In the case of the XPD Asp312Asn polymorphism, our results indicated that individuals carrying the variant heterozygous Asp/Asn showed an increased risk for EC compared to those with the wild-type homozygous Asp/Asp (OR = 1.17, 95%CI: 1.02-1.33). Similarly, a significant association between the XPD Asp312Asn polymorphism and EC was found under the dominant model (OR = 1.18, 95%CI: 1.04-1.34).

plot symmetry (XPD Asp312Asn: \(P = 0.31\) for Asp/Asn vs Asp/Asp, \(P = 0.77\) for Asn/Asn vs Asp/Asp, \(P = 0.06\) for the dominant model, \(P = 0.89\) for the recessive model, and \(P = 0.11\) for the additive model; XPD Lys751Gln: \(P = 0.38\) for Lys/Gln vs Lys/Lys, \(P = 0.99\) for Gln/Gln vs Lys/Lys, \(P = 0.40\) for the dominant model, \(P = 0.86\) for the recessive model, and \(P = 0.69\) for the additive model).

### DISCUSSION

DNA repair enzyme gene polymorphisms that are capable of altering the function or efficiency of damaged DNA repair can lead to genetic instability and carcinogenesis\(^{32}\). A small proportion of published studies have explored the relationship between XPD polymorphisms and EC risk and have yielded inconsistent results\(^{17-31}\). In order to derive a more precise estimation of the relationship, we performed a meta-analysis of 13 case-control studies, including 10 comparisons for the Asp312Asn polymorphism (2373 cases and 3175 controls) and 15 comparisons for the Lys751Gln polymorphism (3226 cases and 5237 controls).

In the case of the XPD Asp312Asn polymorphism, our results indicated that individuals carrying the variant heterozygous Asp/Asn showed an increased risk for EC compared to those with the wild-type homozygous Asp/Asp (OR = 1.17, 95%CI: 1.02-1.33). Similarly, a significant association between the XPD Asp312Asn polymorphism and EC was found under the dominant model (OR = 1.18, 95%CI: 1.04-1.34).

plot symmetry (XPD Asp312Asn: \(P = 0.31\) for Asp/Asn vs Asp/Asp, \(P = 0.77\) for Asn/Asn vs Asp/Asp, \(P = 0.06\) for the dominant model, \(P = 0.89\) for the recessive model, and \(P = 0.11\) for the additive model; XPD Lys751Gln: \(P = 0.38\) for Lys/Gln vs Lys/Lys, \(P = 0.99\) for Gln/Gln vs Lys/Lys, \(P = 0.40\) for the dominant model, \(P = 0.86\) for the recessive model, and \(P = 0.69\) for the additive model).
Table 3  Results of the meta-analysis for the xeroderma pigmentosum group D Lys751Gln polymorphism and esophageal cancer susceptibility

| Study group | Co-dominant model | Dominant model | Recessive model | Additive model |
|-------------|-------------------|---------------|----------------|---------------|
|             | Lys/Gln vs Lys/Lys | Gln/Gln + Lys/Gln vs Lys/Lys | Gln/Gln vs Lys/Gln + Lys/Lys | (2Gln/Gln + Lys/Gln) vs 2(Lys/Gln + Gln/Gln + Lys/Lys) |
|             | OR (95%CI) P Ph | OR (95%CI) P Ph | OR (95%CI) P Ph | OR (95%CI) P Ph |
| Total       | 1.11 (0.94, 1.31) 0.20 0.01 | 1.31 (0.98, 1.75) 0.07 0.03 | 1.14 (0.96, 1.35) 0.14 0.001 | 1.21 (0.92, 1.43) 0.03 0.11 |
| Cancer type |                   |               |                |               |
| ESCC        | 1.13 (0.89, 1.42) 0.31 0.03 | 1.44 (1.01, 2.06) 0.05 0.06 | 1.16 (0.91, 1.49) 0.23 0.01 | 1.26 (0.90, 1.77) 0.17 0.08 |
| EADC        | 1.09 (0.85, 1.40) 0.51 0.02 | 1.26 (1.02, 1.56) 0.03 0.05 | 1.11 (0.85, 1.44) 0.45 0.01 | 1.19 (0.98, 1.45) 0.08 0.25 |
| Ethnicity   |                   |               |                |               |
| Chinese     | 1.10 (0.82, 1.47) 0.53 0.02 | 2.49 (1.44, 4.29) 0.001 0.64 | 1.18 (0.88, 1.60) 0.27 0.01 | 2.37 (1.38, 4.10) 0.002 0.65 |
| Non-Chinese | 1.12 (0.91, 1.36) 0.30 0.03 | 1.13 (0.82, 1.56) 0.45 0.02 | 1.11 (0.89, 1.39) 0.35 0.01 | 1.12 (0.93, 1.34) 0.23 0.14 |

ESCC: Esophageal squamous cell carcinoma; EADC: Esophageal adenocarcinoma; Ph: P value of the Q-test for heterogeneity.

Figure 4 Forest plot for the xeroderma pigmentosum group D Lys751Gln polymorphism when stratified by cancer type in a recessive model comparison. Recessive model: Gln/Gln vs Lys/Gln+Lys/Lys; ESCC: Esophageal squamous cell carcinoma; EADC: Esophageal adenocarcinoma.
Table 5. Study ID OR (95%CI) %weight

| Study ID | OR (95%CI) | %weight |
|----------|------------|---------|
| Chinese  |            |         |
| Xing (2002) | 1.21 (0.24, 6.03) | 1.13 |
| Xing (2003) | 1.18 (0.24, 5.89) | 1.14 |
| Yu (2004)  | 6.65 (1.45, 30.58) | 0.72 |
| Zhai (2005) | 2.01 (0.18, 22.35) | 0.41 |
| Huang (2012) | 2.76 (0.89, 8.53) | 1.50 |
| Li (2013)  | 2.03 (0.75, 5.47) | 2.43 |
| Subtotal (P** = 0.0%, P = 0.648) | 2.37 (1.38, 4.10) | 7.33 |

Non-Chinese

| Study ID | OR (95%CI) | %weight |
|----------|------------|---------|
| Casson (2005) | 1.30 (0.74, 2.31) | 8.15 |
| Ye (2006) | 0.18 (0.63, 2.21) | 7.19 |
| Sobti (2007) | 0.43 (0.18, 1.06) | 6.74 |
| Doecke (2008) | 0.93 (0.62, 1.38) | 20.99 |
| Ferguson (2008) | 1.18 (0.71, 1.98) | 11.18 |
| Tse (2008) | 1.44 (0.94, 2.19) | 14.94 |
| Pang (2009) | 0.65 (0.19, 2.19) | 3.14 |
| Pang (2009) | 1.47 (0.98, 2.20) | 16.01 |
| Subtotal (P** = 34.7%, P = 0.140) | 1.12 (0.93, 1.34) | 92.67 |
| Overall (P** = 32.5%, P = 0.108) | 1.21 (1.02, 1.43) | 100.00 |

Figure 5: Forest plot for the xeroderma pigmentosum group D Lys751Gln polymorphism when stratified by ethnicity in a recessive model comparison. Recessive model: Gln/Gln vs Lys/Gln+Lys/Lys; ESCC: Esophageal squamous cell carcinoma; EADC: Esophageal adenocarcinoma.

Yang R et al: XPD polymorphisms and esophageal cancer risk

Our meta-analysis, which shows a significant association between the XPD Asp312Asn polymorphism and EC susceptibility. A reason may be that the sample sizes of those studies were too small to explore the subtle association between the XPD Asp312Asn polymorphism and EC susceptibility, but the pool of ORs generated from 10 comparisons significantly increases the statistical power.

Many epidemiological studies have also investigated the association between the XPD Lys751Gln polymorphism and EC susceptibility. Xing et al[28], Pan et al[29] and Ferguson et al[30] reported that the Lys751Gln polymorphism in the XPD gene did not influence the risk for ESCC or EADC. However, Yu et al[31], Huang et al[32], Li et al[33], Ye et al[34] and Tse et al[35] revealed a contradictory result, which suggested an increased risk for ESCC and/or EADC in association with the XPD Lys751Gln polymorphism. A more interesting finding revealed by Zhai et al[36] and Casson et al[37] suggested an inverse association, which indicated that the XPD Lys751Gln polymorphism is a protective factor rather than a risk factor for ESCC or EADC. The differences in risk observed in different studies could be partially attributable to the small sample sizes and inappropriate study design. More importantly, the interaction with other polymorphisms and/or particular environmental exposures may also influence the genetic effects of a single polymorphism[35].

There are some limitations to our meta-analysis that should be acknowledged. First, though it is known that the XPD gene has more polymorphisms than just Asp312Asn and Lys751Gln, we focused our meta-analysis on the two most studied polymorphisms due to limited research on other polymorphisms. Second, the studies investigating genetic associations should be based on a...
large sample size, similar study designs and standardised case and control definitions. Third, the XPD gene polymorphisms may influence EC susceptibility in concert with other genes, but we did not have enough data to conduct any gene-gene interaction analyses. Finally, our results were based on single-factor evaluations without adjustment for other risk factors, including BMI, tobacco, alcohol, environmental factors, or lifestyle.

In conclusion, this meta-analysis showed that the XPD Asp312Asn polymorphism may contribute to EC susceptibility, particularly in non-Chinese populations. In addition, the analysis showed that the XPD Lys751Gln polymorphism may also contribute to EC susceptibility, particularly in Chinese individuals. Large, well-designed case-control studies are recommended in order to further enrich the present findings. Future studies should focus on gene-gene and gene-environment interactions to further shed light on the genetics of EC.

**REFERENCES**

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90 [PMID: 21296855 DOI: 10.3322/caac.20107]

2. Islami F, Pourshams A, Nasrollahzadeh D, Kamangar F, Faghimi S, Shakeri R, Abedi-Ardekani B, Merat S, Vahedi H, Semnani S, Abnet CC, Brennan P, Møller H, Saidi F, Dawsey SM, Malekzadeh R, Bolfetta P. Tea drinking habits and oesophageal cancer in a high risk area in northern Iran: population based case-control study. BMJ 2009; 338: b929 [PMID: 19525180 DOI: 10.1136/bmj.b929]

3. Engel LS, Chow WH, Vaughan TL, Hammond MD, Risch HA, Stanford JL, Schoenberg JB, Mayne ST, Dubrow R, Rotter AM, Blatt M, Blazer D, Gail MH, Fraumeni JF. Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst 2003; 95: 1404-1413 [PMID: 13130116]

4. Islami F, Bolfetta P, Ren JS, Pedoieim L, Khatib D, Kamangar F. High-temperature beverages and foods and esophageal cancer risk—a systematic review. Int J Cancer 2009; 125: 491-524 [PMID: 19415743 DOI: 10.1002/ijc.24445]

5. Zhang GH, Mai RQ, Huang B. Meta-analysis of ADH1B and ALDH2 polymorphisms and esophageal cancer risk in China. World J Gastroenterol 2010; 16: 6020-6025 [PMID: 21159780]

6. Wood RD, Mitchell M, Sgouros J, Lindtahl T. Human DNA repair genes. Science 2001; 291: 1284-1289 [PMID: 11181991 DOI: 10.1126/science.1056154]

7. Hoeijmakers JH. Genome maintenance mechanisms are critical for preventing cancer as well as other aging-associated diseases. Mech Ageing Dev 2007; 128: 460-462 [PMID: 17588642 DOI: 10.1016/j.mad.2006.02.002]

8. Fan L, Fuss JG, Cheng QJ, Arvai AS, Hammel M, Roberts VA, Cooper PK, Tainer JA. XPD helicase structures and activities: insights into the cancer and aging phenotypes from XPD mutations. Cell 2008; 133: 789-800 [PMID: 18510924 DOI: 10.1016/j.cell.2008.04.030]

9. Shi Q, Wang LE, Bondy ML, Brewster A, Singleton SE, Wei Q. Reduced DNA repair of benzo[a]pyrene diol epoxide-induced adducts and common XPD polymorphisms in breast cancer patients. Carcinogenesis 2004; 25: 1695-1700 [PMID: 15090466 DOI: 10.1093/carcin/bgh167]

10. Spitz MR, Wu X, Wang Y, Wang LE, Shete S, Amos CI, Guo Z, Lei L, Mohrenweiser H, Wei Q. Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung can-

**COMMENTS**

**Background**
A small proportion of the published studies have explored the relationship between xeroderma pigmentosum group D (XPD) polymorphisms and esophageal cancer (EC) risk and have yielded inconsistent results. In order to derive a more precise estimation of this relationship, we performed a meta-analysis of all of the case-control studies that evaluated the association between the genetic polymorphisms of XPD (Asp312Asn and Lys751Gln) and EC susceptibility.

**Research frontiers**
The XPD enzyme plays an important role in the repair of bulky DNA adducts. Mutations at different sites in the XPD gene may render a higher risk for developing EC. However, the evidence is insufficient given the small sample size.

**Innovations and breakthroughs**
This meta-analysis suggested that the XPD Asp312Asn and Lys751Gln gene polymorphisms are both associated with a significantly increased risk for EC.

**Applications**
This study provided a potential biomarker to identify high-risk individuals for esophageal cancer.

**Terminology**
XPD is an evolutionarily conserved ATP-dependent helicase that plays an important role in the repair of bulky DNA adducts, such as pyrimidine dimers, photoproducts and cross-links.

**Peer review**
The authors clarify the effects of the XPD Asp312Asn and Lys751Gln gene polymorphisms on the risks of esophageal cancer. This is a “delicious” paper.
cancer patients. Cancer Res 2001; 61: 1354-1357 [PMID: 11245433]
11 Hu J, Hall MC, Grossman L, Hedayati M, McCullough DL, Lohman K, Case LD. Deficient nucleotide excision repair capacity enhances human prostate cancer risk. Cancer Res 2004; 64: 1197-1201 [PMID: 14871657].
12 Qin SY, Jiang HX, Lu DH, Zhou Y. Association of interleukin-10 polymorphisms with risk of irritable bowel syndrome: a meta-analysis. World J Gastroenterol 2013; 19: 9472-9480 [PMID: 24409078 DOI: 10.3748/wjg.v19.i49.9472].
13 Yan ZH, Fan Y, Wang XH, Mao Q, Deng GH, Wang YM. Relationship between HLA-DR gene polymorphisms and outcomes of hepatitis B viral infections: a meta-analysis. World J Gastroenterol 2012; 18: 3119-3126 [PMID: 22791948 DOI: 10.3748/wjg.v18.i39.3119].
14 Falvey JD, Bentley MW, Merriman TR, Hampton MB, Barclay ML, Gearry RB, Roberts RL. Macrophage migration inhibitory factor gene polymorphisms in inflammatory bowel disease: an association study in New Zealand Caucasians and a meta-analysis. World J Gastroenterol 2013; 19: 6656-6664 [PMID: 24151396 DOI: 10.3748/wjg.v19.i39.6656].
15 Nie Y, Gu H, Gong J, Wang J, Gong D, Cong X, Chen X, Hu S. Methylenetetrahydrofolate reductase C677T polymorphism and congenital heart disease: a meta-analysis. Clin Chim Acta 2011; 419: 2101-2108 [PMID: 21793759 DOI: 10.1515/CCLM.2011.673].
16 Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical method. BMJ 1997; 315: 629-634 [PMID: 9310560].
17 Liu G, Zhou W, Yeap BY, Su L, Wain JC, Ponoros JM, Nishioka NS, Lynch TJ, Christiani DC. XRCC1 and XPD polymorphisms related to esophageal adenocarcinoma risk. Carcinogenesis 2007; 28: 1254-1258 [PMID: 17264068 DOI: bhm020].
18 Huang CG, Iv GD, Liu T, Liu Q, Feng JG, Lu XM. Polymorphisms of COMT and XPD and risk of esophageal squamous cell carcinoma in a population of Yili Prefecture, in Xinjiang, China. Biomarkers 2011; 16: 37-41 [PMID: 20979431 DOI: 10.3109/1354750X.2010.522732].
19 Tse D, Zhai R, Zhou W, Heist RS, Asomaning K, Su L, Lynch TJ, Wain JC, Christiani DC, Liu G. Polymorphisms of the NER pathway genes, ERCC1 and XPD are associated with esophageal adenocarcinoma risk. Cancer Causes Control 2008; 19: 1077-1083 [PMID: 18478337 DOI: 10.1007/s10552-008-9171-4].
20 Huang CG, Liu T, Lv GD, Liu Q, Feng JG, Lu XM. Analysis of XPD genetic polymorphisms of esophageal squamous cell carcinoma in a population of Yili Prefecture, in Xinjiang, China. Mol Biol Rep 2012; 39: 709-714 [PMID: 21553048 DOI: 10.1007/s11033-011-0789-z].
21 Xing D, Qi J, Miao X, Lu W, Tan W, Lin D. Polymorphisms of DNA repair genes XRCC1 and XPD and their associations with risk of esophageal squamous cell carcinoma in a Chinese population. Int J Cancer 2002; 100: 600-605 [PMID: 12124811 DOI: 10.1002ijc.10528].
22 Xing DY, Qi J, Tan W, Miao XP, Liang G, Yu CY, Lu WF, Zhou CN, Wu M, Lin DX. [Association of genetic polymorphisms in the DNA repair gene XPD with risk of lung and esophageal cancer in a Chinese population in Beijing]. Zhonghua Yi Xue Yi Chuan Xue Zazhi 2003; 20: 35-38 [PMID: 12579149].
23 Yu HP, Wang XL, Sun X, Su YH, Wang YJ, Lu B, Shi LY, Xiong CL, Li YY, Li F, Xu SQ. Polymorphisms in the DNA repair gene XPD and susceptibility to esophageal squamous cell carcinoma. Cancer Genet Cytofgenet 2004; 154: 10-15 [PMID: 15381366 DOI: 10.1016/j.cancergenetic.2004.01.027].
24 Casson AG, Zheng Z, Evans SC, Veugelers PJ, Porter GA, Guernsey DL. Polymorphisms in DNA repair genes in the molecular pathogenesis of esophageal (Barrett) adenocarcinoma. Carcinogenesis 2005; 26: 1536-1541 [PMID: 15878910 DOI: bgi115].
25 Ye W, Kumar R, Bacoova G, Lagergren J, Hemminki K, Nyren O. The XPD751Gln allele is associated with an increased risk for esophageal adenocarcinoma: a population-based case-control study in Sweden. Carcinogenesis 2006; 27: 1835-1841 [PMID: 16571649 DOI: bgi017].
26 Sobi B, Singh J, Kaur P, Pachouri SS, Siddiqui EA, Bindra HS. XRCC1 codon 399 and ERCC2 codon 751 polymorphism, smoking, and drinking and risk of esophageal squamous cell carcinoma in a North Indian population. Cancer Genet Cytofgenet 2007; 175: 91-97 [PMID: 17556064 DOI: S0165-4608(07)00002-7].
27 Doecke J, Zhao ZZ, Pandeya N, Sadeghi S, Stark M, Green AC, Hayward NK, Webb PM, Whiteman DC. Polymorphisms in MGMT and DNA repair genes and the risk of esophageal adenocarcinoma. Int J Cancer 2008; 124: 174-180 [PMID: 18367808 DOI: 10.1002/ijc.23410].
28 Ferguson HR, Wild CP, Anderson LA, Murphy SJ, Johnstone BT, Murray LJ, Watson RG, McGuigan J, Reynolds J, Hardie LJ. No association between hOGG1, XRCC1, and XPD polymorphisms and risk of reflux esophagitis, Barrett’s esophagus, or esophageal adenocarcinoma: results from the factors influencing the Barrett’s adenocarcinoma relationship case-control study. Cancer Epidemiol Biomarkers Prev 2008; 17: 736-739 [PMID: 18349297 DOI: 10.1158/1055-9965.EPI-07-2832].
29 Pan J, Lin J, Izzo JG, Liu Y, Xing J, Huang M, Aiani JA, Wu X. Genetic susceptibility to esophageal cancer: the role of the nucleotide excision repair pathway. Carcinogenesis 2009; 30: 785-792 [PMID: 19270000 DOI: 10.1093/carcin/bgp058].
30 Zhai XD, Mo YN, Xue XQ, Zhao GS, Gao LB, Ai HW, Ye Y. XRCC1 codon 280 and ERCC2 codon 751 polymorphisms and risk of esophageal squamous cell carcinoma in a Chinese population. Bull Cancer 2009; 96: E61-E65 [PMID: 19762325 DOI: 10.1684/bdc.2009.0952].
31 Li RZ, Sun J. Association between XPD gene polymorphisms and esophageal squamous cell carcinoma. Mol Med Rep 2013; 7: 674-678 [PMID: 23229387 DOI: 10.3892/mmr.2012.1215].
32 Arizono K, Osada Y, Kuroda Y. DNA repair gene hOGG1 codon 326 and XRCC1 codon 599 polymorphisms and bladder cancer risk in a Japanese population. Int J Clin Oncol 2008; 13: 186-191 [PMID: 18272472 DOI: 10.1009/jic/o8m176].
33 Duan XL, Gong H, Zeng XT, Ni XB, Yan Y, Chen W, Liu GL. Association between XPD Sp312Asn polymorphism and esophageal cancer susceptibility: a meta-analysis. Asian Pac J Cancer Prev 2012; 13: 3299-3303 [PMID: 22994751].
34 Hirschhorn JN, Lohmueller K, Byrne E, Hirschhorn K. A comprehensive review of genetic association studies. Genet Med 2002; 4: 45-61 [PMID: 11882781 DOI: 10.109700125817-20102030-00002].
35 Ding DP, Ma WL, He XF, Zhang Y. XPD Lys751Gln polymorphism and esophageal cancer susceptibility: a meta-analysis of case-control studies. Mol Biol Rep 2012; 39: 2533-2540 [PMID: 21667112 DOI: 10.1007/s11033-011-0100-x].
36 Yuan L, Cui D, Zhao EJ, Jia CZ, Wang LD, Lu WQ. XPD Lys751Gln polymorphism and esophageal cancer risk: a meta-analysis involving 2288 cases and 4096 controls. World J Gastroenterol 2011; 17: 2343-2348 [PMID: 21653601 DOI: 10.3748/wjg.v17.i18.2343].
